Published - Thu, 26 May 2022
While Covid-19 isn't as dangerous to children as it is to adults,
some children do become seriously ill or die as a result of it. Children were
particularly hard hit by the omicron variant, with those under the age of five
being hospitalized at higher rates than during the previous delta surge. The
announcement comes after months of anxious waiting by parents who are desperate
to vaccinate their infants, toddlers, and preschoolers, especially as COVID-19
cases are on the rise once more.
The three-dose COVID-19 vaccine from
Pfizer protects young children under the age of five from symptomatic
infections. The FDA is expected to make a decision on the approval of
paediatric COVID-19 vaccines by July. Pfizer has had a difficult time
determining its strategy. It aims to give kids a very low dose — one-tenth of
what adults get — but during testing, it was discovered that two shots weren't
quite strong enough for preschoolers.
According to preliminary findings, the
three-dose series is 80% effective in preventing symptomatic Covid-19. We've
discovered that to protect older children and adults from newer variants like
omicron, three doses are required. Scientists measured the children's
neutralizing antibody levels as well as clinical data on infection prevention
to assess the shot's efficacy. They discovered that the safety, immunogenicity,
and efficacy data for three doses in children matched what they saw in adults.
The third dose increases antibody levels in children, providing strong clinical
protection against contagious and immune-evasive Omicron variants/sub-variants.
Parents have expressed dissatisfaction with the length of
time it has taken for the COVID-19 vaccine to be approved for young children.
However, polls show that many parents are hesitant to have their children
vaccinated. According to a survey, only 18 percent of parents of children under
the age of five intend to have their child vaccinated once a vaccine for that
age group is approved. Parents of older children have also been slow to get
their children immunized.
Rigomo is a leading online education platform that offers a wide range of courses to help individuals enhance their skills and achieve their career goals. With our user-friendly interface and expert instructors, we strive to provide high-quality education to everyone, anytime and anywhere. Join us today and take the first step towards a brighter future.
Rigomo is an e-learning platform that was founded in 2019 by a team of dedicated professionals with a passion for revolutionizing the way people learn. The platform offers a range of online courses that cover various industries, including business, technology, healthcare, and more.
Rigomo's courses are designed to be interactive and engaging, with a focus on practical skills that learners can apply in their careers. The platform uses a combination of video lectures, quizzes, and hands-on projects to help learners master the subject matter.
Rigomo is committed to providing affordable and accessible education to people around the world. The platform offers a range of pricing options, including monthly and annual subscriptions, as well as pay-as-you-go options for individual courses.
Since its launch, Rigomo has received numerous accolades for its innovative approach to e-learning. The platform has helped thousands of learners across the globe acquire new skills and advance their careers.
As Rigomo continues to grow, the team remains committed to providing high-quality education that is accessible to all. The platform is constantly updating its courses and features to ensure that learners have access to the latest tools and technologies.
Sun, 12 May 2024
Thu, 25 Apr 2024
Wed, 24 Apr 2024
Write a public review